A network meta-analysis of the effectiveness of different basic preconditioning regiments in allogeneic hematopoietic stem cell transplantation

References

• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: results of the International All Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833. doi:10.1182/blood-2007-10-116582
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Potter M, et al. Comparable results of autologous and allogeneic hematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukemia in first complete molecular remission: an analysis by the acute leukemia working party of the EBMT. Eur J Cancer. 2018;96:73–81. doi:10.1016/j.ejca.2018.03.018
   PubMed Web of Science ®Google Scholar
• Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382–1388. doi:10.1182/blood.V70.5.1382.1382
   PubMed Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–533. doi:10.1182/blood.V49.4.511.511
   PubMed Web of Science ®Google Scholar
• Bertz H, Potthoff K, Mertelsmann R, et al. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant. 1997;19:1169–1173. doi:10.1038/sj.bmt.1700823
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756–763.
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–864. doi:10.1182/blood-2004-02-0414
   PubMed Web of Science ®Google Scholar
• Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468–476. doi:10.1053/bbmt.2002.v8.pm12374451
   PubMed Web of Science ®Google Scholar
• Uberti JP, Agovi MA, Tarima S, et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant. 2011;46(1):34–43. doi:10.1038/bmt.2010.81
   PubMed Web of Science ®Google Scholar
• Salhotra1 A, Hui S, Yang D, et al. Long-term outcomes of patients with acute myelogenous leukemia treated with myeloablative fractionated total body irradiation tbi-based conditioning with a tacrolimus and sirolimus-based graft-versus-host disease prophylaxis regimen: 6-year follow-up from a single center. Biol Blood Marrow Transplant. 2020;26(2):292–299. doi:10.1016/j.bbmt.2019.09.017
   PubMed Web of Science ®Google Scholar
• Kalaycio M, Bolwell B, Rybicki L, et al. BU-vs TBI-based conditioning for adult patients with ALL. Bone Marrow Transplant. 2011;46(11):1413–1417. doi:10.1038/bmt.2010.314
   PubMed Web of Science ®Google Scholar
• Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–3870. doi:10.1182/blood-2013-07-514448
   PubMed Web of Science ®Google Scholar
• Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54(11):2474–2479. doi:10.3109/10428194.2013.779691
   PubMed Web of Science ®Google Scholar
• Wang YH, Ko BS, Liao XW, et al. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem-cell transplantation for acute lymphoblastic leukemia: single tertiary center experience in Taiwan. Biol Blood Marrow Transplant. 2019;25(3):188–199. doi:10.1016/j.bbmt.2018.12.774
   Google Scholar
• Gooptu M, Kim H, Ho V, et al. A Comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation, for allogeneic stem-cell transplantation in the modern era: a cohort analysis. Biol Blood & Marrow Transplant. 2018;24:1733–1740. doi:10.1016/j.bbmt.2018.03.011
   PubMed Web of Science ®Google Scholar
• Jiang Y, Fang X, Sui X, et al. Comparison of different conditioning regimens of haploidentical hematopoietic stem cell transplant in patients with acute myeloid leukemia. Exp Clin Transplant: Off J Middle East Soc Organ Transplant. 2018;16(6):736–744.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol, Oncol. 2013;6(15):2–9.
   PubMedGoogle Scholar
• Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(6):701–709. doi:10.1200/JCO.2011.40.2362
   PubMed Web of Science ®Google Scholar
• Liu DH, Xu LP, Zhang XH, et al. Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. Int J Hematol. 2013;98(6):708–715. doi:10.1007/s12185-013-1460-3
   PubMed Web of Science ®Google Scholar
• Patel SS, Rybici L, Pohlman B, et al. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome ScienceDirect. Hematol Oncol Stem Cell Ther. 2020;13(3):160–165. doi:10.1016/j.hemonc.2019.09.002
   PubMedGoogle Scholar
• Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukemia: an open-label, multicenter, randomized, phase 3 trial. Lancet Oncol. 2015;16(15):1525–1536. doi:10.1016/S1470-2045(15)00200-4
   PubMed Web of Science ®Google Scholar
• Zhang W-P, Wang Z-W, Hu X-X, et al. Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone Marrow Transplant. 2019;54(6):894–902. doi:10.1038/s41409-018-0356-5
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923–1930. doi:10.1182/blood-2004-03-0803
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med. 2010;363(22):2091–2101. doi:10.1056/NEJMoa1004383
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kurosawa S, Tajima K, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:553–559. doi:10.1038/bmt.2015.330
   PubMed Web of Science ®Google Scholar
• Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016. doi:10.1182/blood.V75.4.1011.1011
   PubMed Web of Science ®Google Scholar
• Kawamura K, Kako S, Mizuta S, et al. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transplant. 2017;23:2079–2087. doi:10.1016/j.bbmt.2017.09.003
   PubMed Web of Science ®Google Scholar
• Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–1161. doi:10.1200/JCO.2016.70.7091
   PubMed Web of Science ®Google Scholar
• Santos GW. Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Ann N Y Acad Sci. 1995;770:1–7. doi:10.1111/j.1749-6632.1995.tb31039.x
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Camitta B, Gaynon P, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence based review. Biol Blood Marrow Transplant. 2012;18(4):505–522. doi:10.1016/j.bbmt.2011.12.585
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–1353. doi:10.1056/NEJM198312013092202
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347–1353. doi:10.1056/NEJM198312013092202
   PubMed Web of Science ®Google Scholar
• Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382–1388. doi:10.1182/blood.V70.5.1382.1382
   PubMed Web of Science ®Google Scholar
• Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–3878. doi:10.1182/blood-2013-08-519009
   PubMed Web of Science ®Google Scholar
• Lee J-H, Joo Y-D, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31(6):701–709. doi:10.1200/JCO.2011.40.2362
   PubMed Web of Science ®Google Scholar
• Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008;14(6):672–684. doi:10.1016/j.bbmt.2008.03.009
   PubMed Web of Science ®Google Scholar
• Or R, Weiss L, Teiman S. Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation. Blood. 1997;90(1):461–471.
   Web of Science ®Google Scholar